Yesterday, after the markets closed, as scheduled, Judge Miranda Du, of the federal District Court of Nevada reached her highly anticipated decision in the Abbreviated New Drug Application (ANDA) (i.e. generic drug) litigation between Amgen and generic company defendants Hikma and Dr. Reddy's Laboratories related to AMRN's Vascepa. I attempt to break down the significance of this ruling so that biopharma investors can better understand what it means for AMRN and these generic companies. A free sign-up* is required. Just click the link below (or paste the URL in your browser if it doesn't open).
*We only use your email for periodic correspondence from Amp about biopharma companies we analyze or for a newsletter that we might send out from time to time.